Virtual Library

Start Your Search

Yanwei Zhang



Author of

  • +

    EP1.03 - Biology (ID 193)

    • Event: WCLC 2019
    • Type: E-Poster Viewing in the Exhibit Hall
    • Track: Biology
    • Presentations: 2
    • Now Available
    • Moderators:
    • Coordinates: 9/08/2019, 08:00 - 18:00, Exhibit Hall
    • +

      EP1.03-12 - IL-10 Promotes Tumor Aggressiveness in Non-Small Cell Lung Cancer via Down-Regulated the Expression Level of miR-125b (Now Available) (ID 1776)

      08:00 - 18:00  |  Presenting Author(s): Yanwei Zhang

      • Abstract
      • Slides

      Background

      IL-10 is an anti-inflammatory factor with bi-directional regulation of tumor immunity. While, the role and mechanism of IL-10 in lung cancer is not clear. The aim of the present study was to identify the potential mechanisms of IL-10 in lung carcinogenesis.

      Method

      RT-PCR was used to detect the expression of miRNAs and mRNAs. CKK8 and flow cytometry assays was performed for the function experiments. Microarray analysis and IPA analysis were used to predict the potential signal pathway.

      Result

      IL-10 was found significantly associated with the risk of non-small cell lung cancer (NSCLC). Meanwhile, the expression level of miR-125b in NSCLC cell line was dramatically decreased when stimulated by IL-10. The results of cell function experiments showed that miR-125b inhibited the tumor promoting effects of IL-10 in NSCLC. Then, microarray and IPA analysis found that IGF-1 signaling pathway was significantly activated after down-regulated the expression of miR-125b.2.jpg

      Conclusion

      IL-10 promotes tumor aggressiveness via down-regulated the expression level of miR-125b in lung cancer.

      3.jpg

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.

    • +

      EP1.03-22 - Prognostic Value of Serum Inflammation Biomarkers in Early Stage Lung Adenocarcinoma (Now Available) (ID 1753)

      08:00 - 18:00  |  Presenting Author(s): Yanwei Zhang

      • Abstract
      • Slides

      Background

      Non-small cell lung cancer is the main cause of cancer-related death worldwide, with a low 5-year survival rate even in early-stage. And adenocarcinoma accounts for the majority of all Non-small cell lung cancer cases. Biomarkers to identify prognosis of early stage lung cancer are needed. Increasing evidences indicate a relationship between inflammation and lung carcinogenesis. One of our previous studies found inflammation biomarkers, BLC and MDC, are significantly related with the risk of early stage lung cancer. The present study was performed to evaluated the value of inflammation biomarker in predicting the prognosis of early stage lung adenocarcinoma.

      Method

      Ten inflammation biomarkers were tested by Luminex bead-based assay in 157 patients with resected early-stage lung adenocarcinoma (IA-IIB) from whom serum samples were collected pre-surgery.

      Result

      A total of 152 early stage lung adenocarcinoma patients were analyzed in this study. The mean age (SD) of was 59.9 (9.4) years. 58.6% of them were females, and never smokers accounted for 84.0%. By TNM stage, 109 (71.7%) patients were at stage I and 43 (28.3%) at stage II. The median follow-up time was 60.6 months. Patients with higher MIG levels were at a 70% reduced risk of recurrence compared with patients with lower MIG levels (HR=0.3, 95% CI: 0.1–0.7, p=0.0035). As for BLC, patients with higher levels had the risk of recurrence decreased by 50% (HR=0.5, 95% CI: 0.3–0.9, p=0.031) compared with patients with lower levels. After the Bonferroni correction, only MIG was significantly associated with the recurrence risk of early stage lung adenocarcinoma. For overall survival (OS), patients with higher MIG levels were still have a reduced dead risk compared with the lower group (p=0.0065).

      Conclusion

      Our results demonstrate for the first time that pretreatment MIG level was identified as a protective factor for the prognosis of early stage lung adenocarcinoma.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.

  • +

    MA25 - Precision Medicine in Advanced NSCLC (ID 352)

    • Event: WCLC 2019
    • Type: Mini Oral Session
    • Track: Advanced NSCLC
    • Presentations: 1
    • Now Available
    • +

      MA25.09 - Navigating Anlotinib Precision Therapy Through the Genetic Profiling of Circulating DNA in Non-Small Cell Lung Cancer Patients (Now Available) (ID 1055)

      14:30 - 16:00  |  Author(s): Yanwei Zhang

      • Abstract
      • Presentation
      • Slides

      Background

      Anlotinib is an oral multi-targeted anti-angiogenic drug, and its clinical predictor for non-small cell lung cancer (NSCLC) patients is still elusive. The aim of this study is to screen predictor for anlotinib via non-invasive genetic profiling of plasma cell free DNA and circulating tumor DNA (cfDNA & ctDNA).

      Method

      Tumor-specific target capture to profile the circulating DNA of ALTER0303 (Evaluating NSCLC clinical anti-tumor efficacy through anlotinib therapy) study participants. Acquired mutations were screened out via comparing genetic profiling between baseline (BL) and progression disease (PD), and were used for anlotinib stratification. Based on the sequencing data at BL, tumor mutation index (TMI) was established from three independent predictors germline and somatic mutation burden (G+S MB), nonsynonymous and synonymous mutation burden (N+S MB) and unfavorable mutation score (UMS), and was used for predicting anlotinib responders. In addition, TMI combined with IDH1Exon4 mutation status also be examined for serving as predictor for anlotinib stratification.

      Result

      Our data firstly indicated no benefit (NB, PFS ≤ 45 days) patients can be mainly excluded via analysis of ARID1A and BRCA2 genetic profiling. Secondly, for the no durable benefit (NDB, 45 days < PFS ≤ 130 days) and durable clinical benefit (DCB, PFS > 130 days) patients, harboring lower mutation burden (G+S MB, N+S MB, and UMS) received more benefit from anlotinib therapy. Subsequently, we found the predictor-TMI can predict anlotinib responders upon discovery cohort (Median PFS: 210 days vs 126 days; p = 0.0238; AUC = 0.77), and validation cohort (Median PFS: 210 days vs 127 days; p = 0.0352) and all patients (Median PFS: 210 days vs 127 days; p = 0.0044) more effectively. Furthermore, the IDH1Exon4 mutation was identified as an unfavorable factor to anlotinib therapy under TMI-based stratification. Lastly, the TMI plus IDH1Exon4 mutation status predict response to anlotinib significantly (Median PFS: 210 days vs 127 days, p < 0.0001, AUC = 0.90; Median OS: 423 days vs 162 days, p < 0.0001, AUC = 0.80).

      Conclusion

      This study provides circulating DNA sequencing-based stratification for underlying anlotinib responders via non-invasive approach, and thus potentially improve clinical outcome for NSCLC patients at 3rd line.

      Only Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login, select "Add to Cart" and proceed to checkout. If you would like to become a member of IASLC, please click here.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.